Do analysts rate RVP or CLGN?

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,068.04%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CollPlant Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

CollPlant Biotechnologies (CLGN) Competitors

$0.36 -0.01 (-2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 0.00 (0.00%)

As of 06:54 PM Eastern

Compare

CLGN vs. CODX, FEMY, LFWD, RVP, and IRIX

Should you buy CollPlant Biotechnologies stock or one of its competitors? MarketBeat compares CollPlant Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CollPlant Biotechnologies include Co-Diagnostics (CODX), Femasys (FEMY), Lifeward (LFWD), Retractable Technologies (RVP), and IRIDEX (IRIX). These companies are all part of the "medical equipment" industry.

How does CollPlant Biotechnologies compare to Co-Diagnostics?

CollPlant Biotechnologies (NASDAQ:CLGN) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, CollPlant Biotechnologies and CollPlant Biotechnologies both had 2 articles in the media. CollPlant Biotechnologies' average media sentiment score of 1.44 beat Co-Diagnostics' score of 0.44 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
CollPlant Biotechnologies	Positive
Co-Diagnostics	Neutral

CollPlant Biotechnologies has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

CollPlant Biotechnologies presently has a consensus target price of $11.50, indicating a potential upside of 3,068.04%. Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 1,283.20%. Given CollPlant Biotechnologies' higher probable upside, equities analysts clearly believe CollPlant Biotechnologies is more favorable than Co-Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CollPlant Biotechnologies has a net margin of -683.68% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

CollPlant Biotechnologies has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.21	-$11.49M	-$1.45	N/A
Co-Diagnostics	$620K	29.04	-$46.90M	-$15.77	N/A

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 5.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CollPlant Biotechnologies beats Co-Diagnostics on 10 of the 13 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Femasys?

Femasys (NASDAQ:FEMY) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Femasys has a net margin of -521.97% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

CollPlant Biotechnologies has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	6.24	-$18.63M	-$0.27	N/A
CollPlant Biotechnologies	$2.37M	2.21	-$11.49M	-$1.45	N/A

Femasys has a beta of -2.23, meaning that its stock price is 323% less volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Femasys currently has a consensus price target of $106.67, indicating a potential upside of 2,155.11%. CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,068.04%. Given CollPlant Biotechnologies' higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Femasys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

65.3% of Femasys shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 7.6% of Femasys shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Femasys had 4 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 6 mentions for Femasys and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 1.44 beat Femasys' score of 0.13 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Neutral
CollPlant Biotechnologies	Positive

Summary

Femasys and CollPlant Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Lifeward?

CollPlant Biotechnologies (NASDAQ:CLGN) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CollPlant Biotechnologies has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

In the previous week, Lifeward had 8 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 10 mentions for Lifeward and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 1.44 beat Lifeward's score of 0.04 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
CollPlant Biotechnologies	Positive
Lifeward	Neutral

CollPlant Biotechnologies presently has a consensus target price of $11.50, indicating a potential upside of 3,068.04%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 41.44%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, research analysts clearly believe CollPlant Biotechnologies is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Lifeward has a net margin of -123.66% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Lifeward	-123.66%	-243.14%	-97.39%

CollPlant Biotechnologies has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.21	-$11.49M	-$1.45	N/A
Lifeward	$22.03M	0.90	-$19.91M	-$19.66	N/A

Summary

CollPlant Biotechnologies beats Lifeward on 10 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Retractable Technologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Retractable Technologies has a net margin of -41.11% compared to CollPlant Biotechnologies' net margin of -683.68%. Retractable Technologies' return on equity of -17.15% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Retractable Technologies has higher revenue and earnings than CollPlant Biotechnologies. Retractable Technologies is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$37.15M	0.56	-$7.01M	-$0.21	N/A
CollPlant Biotechnologies	$2.37M	2.21	-$11.49M	-$1.45	N/A

CollPlant Biotechnologies has a consensus price target of $11.50, indicating a potential upside of 3,068.04%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, CollPlant Biotechnologies had 2 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 0 mentions for Retractable Technologies. CollPlant Biotechnologies' average media sentiment score of 1.44 beat Retractable Technologies' score of 0.00 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Retractable Technologies	Neutral
CollPlant Biotechnologies	Positive

Summary

CollPlant Biotechnologies beats Retractable Technologies on 9 of the 16 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

IRIDEX has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

In the previous week, IRIDEX had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for IRIDEX and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 1.44 beat IRIDEX's score of 0.87 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
IRIDEX	Positive
CollPlant Biotechnologies	Positive

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IRIDEX presently has a consensus target price of $3.00, suggesting a potential upside of 165.49%. CollPlant Biotechnologies has a consensus target price of $11.50, suggesting a potential upside of 3,068.04%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has a net margin of -6.23% compared to CollPlant Biotechnologies' net margin of -683.68%. CollPlant Biotechnologies' return on equity of -218.81% beat IRIDEX's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.23%	-1,204.74%	-11.16%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

IRIDEX has higher revenue and earnings than CollPlant Biotechnologies. IRIDEX is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.37	-$4.44M	-$0.19	N/A
CollPlant Biotechnologies	$2.37M	2.21	-$11.49M	-$1.45	N/A

Summary

CollPlant Biotechnologies beats IRIDEX on 8 of the 14 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.35M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-0.25	18.83	24.65	23.63
Price / Sales	2.21	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.76	8.00	10.43	6.70
Net Income	-$11.49M	$23.89M	$3.56B	$337.26M
7 Day Performance	-9.23%	-3.49%	-1.39%	-1.41%
1 Month Performance	-9.75%	1.03%	0.86%	1.15%
1 Year Performance	-79.61%	34.39%	19.42%	22.61%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	3.0134 of 5 stars	$0.36 -2.2%	$11.50 +3,068.0%	-78.6%	$5.35M	$2.37M	N/A	70	Positive News Analyst Upgrade Short Interest Decrease
CODX Co-Diagnostics	2.0478 of 5 stars	$6.22 +0.3%	$67.50 +985.2%	-49.7%	$22.85M	$620K	N/A	100	Short Interest Increase Gap Down
FEMY Femasys	2.0303 of 5 stars	$0.37 -1.7%	$5.33 +1,336.4%	-67.2%	$22.82M	$2.38M	N/A	30	Stock Split Short Interest Increase
LFWD Lifeward	2.7375 of 5 stars	$7.68 -3.4%	$10.00 +30.2%	-51.9%	$22.38M	$22.03M	N/A	60
RVP Retractable Technologies	N/A	$0.67 -4.0%	N/A	+3.3%	$20.03M	$37.15M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. CODX, FEMY, LFWD, RVP, and IRIX

How does CollPlant Biotechnologies compare to Co-Diagnostics?

Summary

How does CollPlant Biotechnologies compare to Femasys?

Summary

How does CollPlant Biotechnologies compare to Lifeward?

Summary

How does CollPlant Biotechnologies compare to Retractable Technologies?

Summary

How does CollPlant Biotechnologies compare to IRIDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. CODX, FEMY, LFWD, RVP, and IRIX

How does CollPlant Biotechnologies compare to Co-Diagnostics?

Does the media favor CLGN or CODX?

Which has more risk & volatility, CLGN or CODX?

Do analysts recommend CLGN or CODX?

Is CLGN or CODX more profitable?

Which has preferable earnings and valuation, CLGN or CODX?

Do insiders & institutionals believe in CLGN or CODX?

Summary

How does CollPlant Biotechnologies compare to Femasys?

Is FEMY or CLGN more profitable?

Which has preferable earnings & valuation, FEMY or CLGN?

Which has more volatility and risk, FEMY or CLGN?

Do analysts rate FEMY or CLGN?

Do insiders and institutionals believe in FEMY or CLGN?

Does the media prefer FEMY or CLGN?

Summary

How does CollPlant Biotechnologies compare to Lifeward?

Do institutionals & insiders believe in CLGN or LFWD?

Which has more risk and volatility, CLGN or LFWD?

Does the media favor CLGN or LFWD?

Do analysts prefer CLGN or LFWD?

Is CLGN or LFWD more profitable?

Which has better earnings & valuation, CLGN or LFWD?

Summary

How does CollPlant Biotechnologies compare to Retractable Technologies?

Which has more risk and volatility, RVP or CLGN?

Is RVP or CLGN more profitable?

Which has preferable valuation and earnings, RVP or CLGN?

Do analysts rate RVP or CLGN?

Do institutionals and insiders believe in RVP or CLGN?

Does the media refer more to RVP or CLGN?

Summary

How does CollPlant Biotechnologies compare to IRIDEX?

Which has more volatility & risk, IRIX or CLGN?

Does the media prefer IRIX or CLGN?

Do insiders and institutionals have more ownership in IRIX or CLGN?

Do analysts prefer IRIX or CLGN?

Is IRIX or CLGN more profitable?

Which has better valuation and earnings, IRIX or CLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools